VBI Vaccines Inc VBIV shares are trading higher after the company announced the collaboration with the National Research Council of Canada to develop a pan-coronavirus vaccine candidate targeting coronavirus, SARS and MERS.
VBI Vaccines is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology.
VBI Vaccines shares are trading up 15.44% to $1.08 at time of publication. The stock has a 52-week high of $2.20 and a 52-week low of 47 cents.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
